Effects of olmesartan vs irbesartan on metabolic parameters and visfatin in hypertensive obese women

Background: Angiotensin II reg- ulates the production of adipokines. The objective was to study the effect of treatment with irbesartan versus olmesartan in obese hypertensive women. Subjects: A sample of 34 obese hypertensive women was analyzed in a prospective way with a randomized trial. Patients were randomized to irbe- sartan (300 mg/day) or olmesartan (40 mg/day) for 3 months. Weight, body mass index, blood pres- sure, basal glucose, insulin, total cholesterol, LDL- cholesterol, HDL-cholesterol, triglycerides, HOMA and visfatin were determined at basal time and af- ter 3 months of treatment. Results: Thirty four patients gave informed con- sent and were enrolled in the study. A significative decrease in systolic and diastolic blood pressures was reached without changes in weight. Patients treated with olmesartan had a significative de- crease of total cholesterol, LDL cholesterol, in- sulin, HOMA and visfatin levels. Decrease in total cholesterol and LDL cholesterol was similar with both angiotensin receptor blockers. Decrease in insulin (2.28±2.77 vs 0.66±4.4 mUI/L: p<0.05), HOMA (0.69±1.1 vs 0.48±1.6 units: p<0.05) and vis- fatin (5.16±13 vs 1.85±9.1 ng/ml: p<0.05)levels was higher in olmesartan than irbesartan group. Conclusion: The administration of olmesar- tan improved blood pressure, insulin, HOMA, visfatin and lipid profile in hypertensive obese women. Irbesartan improved blood pressure and lipid levels.